Baltimore, Md.-based Profectus BioSciences, a biotech developing new strategies to attack HIV, received a $200,000 small-business innovation grant from the National Institutes of Health to improve the effectiveness of anti-HIV antibodies. Last month, the company received a similar $300,000 grant (PDF link), just a few days after the company raised $3 million in a private placement.

Profectus, which was spun out of the Institute for Human Virology in 2005, has so far rased a total of at least $6.5 million.